In the graveyard of failed drug trials, Insitro is betting that data—not just serendipity—holds the cure. By fusing machine learning with wet-lab biology, Daphne Koller’s startup isn't just iterating on drugs; it's rewriting the discovery playbook.

"Insitro isn't just using AI as a tool; they are using it as the fundamental infrastructure for drug discovery."

The tech stack reveals their hybrid nature. They utilize WordPress for their public face but rely on Vue.js, Bootstrap, and Cloudflare for performance and scalability. The presence of Mouseflow and Google Analytics suggests a rigorous, data-obsessed approach to even their user acquisition and candidate funnel—tracking behavior to optimize the 'candidate experience' just as they optimize molecular pathways.

• Vertical Integration: Unlike many biotech startups that outsource discovery, Insitro builds internal wet-lab capabilities paired with ML.
• The 'Koller' Factor: Founded by Daphne Koller (co-founder of Coursera), the company benefits from immense credibility in both academia and Silicon Valley.
• Targeting Complex Biology: They focus on diseases where traditional methods have failed, using data to cut through biological noise.